Study reveals inequities in access to CAR T cell therapy

Patients being treated for B-cell non-Hodgkin’s Lymphoma (NHL) who are part of minority populations may not have equal access to cutting-edge CAR T cell therapies, according to a new analysis led by researchers from the Perelman School of Medicine at the University of Pennsylvania and published today in NEJM Evidence.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup